Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 5.5% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care (TNDM) operates in the automated insulin delivery systems sector, generating revenue mainly from pump sales and disposable supplies. The stock witnessed a downward movement today.

Why is Tandem Diabetes Care, Inc. going down?

TNDM stock is down 5.5% on May 13, 2026 17:16

• Tandem Diabetes Care (TNDM) stock saw a significant decrease of 14.14% in after-hours trading, despite achieving record revenue and surpassing EPS estimates in Q1 2026.
• The initiation of coverage by Benchmark with a 'Hold' rating, showcasing varied analyst views and possible volatility, may have led to investor uncertainty.
• A research report by StockStory assigning an "Underperform" rating due to worries regarding modest sales growth and high valuation in comparison to business quality could have impacted the bearish trend.
• Despite making positive strides operationally and confirming full-year guidance, investor apprehensions about valuation, expense control, and long-term trends might have influenced the stock's decline.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

Tandem Diabetes Care (TNDM) loses 26.5% in 4 weeks, here's why a trend reversal may be around the corner

This article discusses the recent 26.5% drop in Tandem Diabetes Care's (TNDM) stock price over the last four weeks. It suggests that despite the significant decline, a trend reversal could be imminent. The analysis likely highlights underlying factors that might contribute to a potential rebound for the company's stock.

https://www.msn.com/en-us/money/topstocks/tandem-diabetes-care-tndm-loses-26-5-in-4-weeks-here-s-why-a-trend-reversal-may-be-around-the-corner/ar-AA230D1D?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1

TNDM Initiated Coverage by Benchmark -- Rating Set to Hold

Benchmark has initiated coverage on Tandem Diabetes Care (TNDM) with a 'Hold' rating, citing a mixed landscape of analyst opinions and potential volatility. Despite the GF Value™ indicating the stock is 50.4% undervalued, its GF Score™ of 69/100 suggests fair long-term return potential with strong growth prospects but caution on valuation. Insider activity shows minimal selling and no buying in the last three months, prompting investors to monitor TNDM closely.

https://www.gurufocus.com/news/8850972/tndm-initiated-coverage-by-benchmark-rating-set-to-hold

Tandem Diabetes Care, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:TNDM)

Tandem Diabetes Care, Inc. (TNDM) reported its Q1 2026 earnings, with an EPS of -$0.30, beating estimates by $0.14, and revenue of $247.22M, surpassing expectations by $6.68M and showing a 5.46% year-over-year increase. This article presents the slide deck from the company's earnings call, published on May 11, 2026.

https://seekingalpha.com/article/4902686-tandem-diabetes-care-inc-2026-q1-results-earnings-call-presentation

Tandem Diabetes (TNDM) Research Report

StockStory's research report on Tandem Diabetes (TNDM) assigns an "Underperform" rating, citing concerns over soft sales growth, negative returns on capital, and poor expense management despite exceeding Q1 2026 revenue and EPS estimates. The report highlights the company's high valuation relative to its business quality and declining long-term EPS and ROIC trends, suggesting better opportunities exist in the market. Tandem Diabetes specializes in automated insulin delivery systems, with its revenue primarily from pump sales and disposable supplies.

https://stockstory.org/us/stocks/nasdaq/tndm

Earnings call transcript: Tandem Diabetes Care Q1 2026 sees record sales, stock drops

Tandem Diabetes Care reported record revenue of $247.22 million and an EPS of -0.3 for Q1 2026, surpassing analyst expectations. Despite strong financial performance and positive operational progress, including new product launches and market expansion, the company's stock dropped significantly by 14.14% in after-hours trading due to investor concerns. The company reaffirmed its full-year 2026 guidance, expecting continued growth driven by new technologies and a multi-channel business model.

https://m.investing.com/news/transcripts/earnings-call-transcript-tandem-diabetes-care-q1-2026-sees-record-sales-stock-drops-93CH-4677651?ampMode=1

Trending Today

0x ($ZRX) Crypto Forecast: Down 9.1% Today

Chainlink ($LINK) Crypto Forecast: Down 5.3% Today

Solana ($SOL) Crypto Forecast: Down 5.1% Today

QTUM ($QTUM) Crypto Forecast: Down 5.3% Today

Moderna Inc. ($MRNA) Stock Forecast: Down 5.4% Today

Waters Corporation ($WAT) Stock Forecast: Down 5.0% Today

Aramark ($ARMK) Stock Forecast: Up 5.1% Today

NRG Energy Inc. ($NRG) Stock Forecast: Down 5.1% Today

Accenture plc Class A (Ireland) ($ACN) Stock Forecast: Down 6.6% Today

Palo Alto Networks Inc. ($PANW) Stock Forecast: Up 5.3% Today

Tandem Diabetes Care, Inc. Price History

30.03.2026 - TNDM Stock was up 6.0%

• Tandem Diabetes Care disclosed upcoming conference appearances at two notable investor conferences, hinting at positive prospects and potentially exciting updates for investors.
• The FDA clearance for Tandem's Control-IQ+ automated insulin delivery technology for pregnancy in Type 1 Diabetes may have increased investor confidence in the company's innovative products and market potential.
• Vanguard Portfolio Management's substantial investment in Tandem Diabetes Care underscores investor interest and confidence in the company's future growth prospects.
• The overview of Tandem's market opportunity, dedication to innovation, and emphasis on commercial transformation likely contributed to the market's bullish trend as investors recognize the company's strong position in the global diabetes market.

30.03.2026 - TNDM Stock was up 7.6%

• Tandem Diabetes Care's stock experienced a strong bullish movement today.
• The bullish trend could be attributed to positive market sentiment driven by an increased price target for TNDM, highlighting the company's new pay-as-you-go program and Mobi Tubeless product as drivers for future revenue growth.
• Additionally, the FDA clearance for Tandem's Control-IQ+ automated insulin delivery technology for pregnancy in Type 1 Diabetes could have further boosted investor confidence in the company's innovative products and market potential.
• Significant stake in Tandem Diabetes Care Inc. by Vanguard Portfolio Management could also indicate institutional investor confidence in the company's long-term growth prospects.

13.04.2026 - TNDM Stock was down 5.5%

• Tandem Diabetes Care (TNDM) stock saw a significant decrease of 14.14% in after-hours trading, despite achieving record revenue and surpassing EPS estimates in Q1 2026.
• The initiation of coverage by Benchmark with a 'Hold' rating, showcasing varied analyst views and possible volatility, may have led to investor uncertainty.
• A research report by StockStory assigning an "Underperform" rating due to worries regarding modest sales growth and high valuation in comparison to business quality could have impacted the bearish trend.
• Despite making positive strides operationally and confirming full-year guidance, investor apprehensions about valuation, expense control, and long-term trends might have influenced the stock's decline.

01.04.2026 - TNDM Stock was up 7.7%

• Tandem Diabetes Care (TNDM) experienced a strong bullish movement recently.
• Vanguard Capital Management's significant passive institutional investment of over 3.5 million shares in TNDM may have instilled confidence in other investors, contributing to the bullish trend.
• The raised price target by TD Cowen and the positive outlook on TNDM's new products driving future revenue growth likely attracted more investors to the stock.
• The announcement of upcoming conference presentations by Tandem Diabetes Care could have also generated excitement and optimism among investors, further fueling the bullish momentum.

28.03.2026 - TNDM Stock was down 6.6%

• The decrease in Tandem Diabetes Care's stock today may be due to profit-taking by investors following a period of positive momentum.
• Despite the favorable FDA clearance for the utilization of Control-IQ+ technology in pregnancy, the market's reaction might have been adverse as a result of already high expectations priced into the stock.
• The upgraded rating by Truist Securities and enthusiasm regarding the new pharmacy distributor model could have already been considered in the stock price, leading to a sell-off after the news.
• Investor concerns about the company's capacity to maintain growth and market presence in the competitive diabetes management sector may be contributing to a bearish outlook in the market.

28.03.2026 - TNDM Stock was down 5.5%

• The FDA clearance for Tandem Diabetes Care's Control-IQ+ automated insulin delivery technology for use in pregnancy complicated by type 1 diabetes, while positive news, might have raised concerns about potential competition in the market leading to a bearish sentiment.
• Despite positive analyst upgrades from Truist Securities and Piper Sandler on Tandem's new pharmacy distributor model and strategy, the market may have reacted negatively due to profit-taking by investors after recent gains.
• Tandem Diabetes Care's strategic transformation initiatives outlined at the TD Cowen 46th Annual Health Care Conference could be seen as promising for the company's future growth, but the market may have interpreted them as long-term investments impacting short-term profitability, contributing to the bearish movement.
• Overall, the bearish movement in TNDM stock today could be a result of a combination of profit-taking, market competition concerns, and short-term impact of strategic transformations on profitability.

08.04.2026 - TNDM Stock was down 9.7%

• Despite strong Q1 2026 financial results and strategic advancements, Tandem Diabetes Care's stock experienced a bearish movement.
• Concerns about the company's transition to a pay-as-you-go pharmacy model may have led to the market's negative reaction, with analysts predicting a potential near-term revenue decline and impact on earnings per share.
• Investors could be cautious due to short-term challenges from the operational shift, despite the company's positive long-term outlook and innovations in diabetes technology.
• The bearish movement might also result from profit-taking actions following the stock's recent strong performance and analyst upgrades, prompting investors to reassess their Tandem Diabetes Care positions.

04.04.2026 - TNDM Stock was down 5.0%

• A notable passive institutional investment by Vanguard Capital Management in Tandem Diabetes Care may have indicated lack of confidence in the company's future, influencing the bearish trend.
• Despite TD Cowen increasing TNDM's price target and maintaining a Buy rating, the market's negative reaction to the company's announcement of upcoming investor conference details might have led to market pessimism.
• Investors possibly engaged in profit-taking due to the anticipation of Tandem Diabetes Care's presentations at upcoming investor conferences, which could have driven down the stock price.
• Shifting market sentiment towards medical stocks priced below $30 could have impacted Tandem Diabetes Care's stock performance, notwithstanding positive forecasts for future revenue growth.

06.04.2026 - TNDM Stock was down 5.2%

• The FDA clearance for Tandem's Control-IQ+ technology for pregnant individuals with type 1 diabetes could have raised concerns among investors about potential regulatory and pricing pressures, leading to the bearish market movement.
• The disclosure of significant ownership stakes by institutional investors like Voya Financial and Vanguard Capital Management might have influenced market sentiment, contributing to the downward trend in TNDM stock.
• Despite TD Cowen raising Tandem Diabetes' price target and maintaining a Buy rating, the overall market reaction to the news about the pay-as-you-go program and Mobi Tubeless product may have been overshadowed by other factors, resulting in the bearish movement observed today.

11.04.2026 - TNDM Stock was down 6.2%

• Tandem Diabetes Care (TNDM) displayed a reduction in losses during Q4 2025, challenging bearish views and suggesting the potential for improved profit margins going forward.
• Mizuho Securities maintained a Hold rating on TNDM while increasing the target price to $24, reflecting their continuous evaluation of the company's financial outlook.
• Despite receiving FDA clearance for its Control-IQ+ technology for pregnancy use, TNDM's stock price has declined year-to-date, prompting discussions about undervaluation and a potential fair value of $30.76.
• Tandem Diabetes Care announced strong financial results for Q1 2026, including record pump shipments and sales, showcasing its dedication to innovation and expansion.

06.04.2026 - TNDM Stock was down 6.0%

• Investor concerns about potential dilution of existing shares following an upsized private placement of convertible senior notes may have influenced the negative market sentiment.
• Despite the FDA clearance for Control-IQ+ technology for pregnant individuals with type 1 diabetes, worries about execution risks related to new distribution models and regulatory pressures could have outweighed the positive news.
• The disclosure of substantial ownership stakes by institutional investors such as Voya Financial and Vanguard Capital Management could have led to increased selling pressure as some investors may view this as a lack of confidence in TNDM's short-term prospects.
• Insights driven by pricing data and AI-generated trading strategies pointing out choppy conditions and diverging sentiment across different time frames might have exacerbated uncertainty and contributed to the stock's bearish movement today.

12.04.2026 - TNDM Stock was up 5.0%

• Tandem Diabetes Care reported impressive Q1 2026 earnings, beating estimates with a revenue of $247.22 million and an EPS of -$0.30, showing a 5.46% year-over-year increase. This positive financial performance likely fueled investor confidence and contributed to the bullish movement in the stock.
• Despite the record sales and positive operational progress, the stock initially dropped by 14.14% in after-hours trading, possibly due to investor concerns. However, the company's reaffirmation of its full-year guidance and growth expectations from new technologies and business models could have reassured investors, leading to the bullish trend.
• Truist Financial maintaining a Buy rating on Tandem Diabetes Care, albeit with a slightly reduced target price, indicates continued optimism in the company's future prospects. This vote of confidence might have further supported the bullish momentum in the stock.
• Tandem Diabetes Care's strategic initiatives, such as expanding internationally, launching new products like Control-IQ+ for pregnant women, and addressing supply chain challenges, demonstrate a proactive approach to growth. These factors, combined with the positive earnings report, likely contributed to the bullish market movement of the stock.